Gracell Biotechnologies Inc. (GRCL) Cash Flow Annual - Discounting Cash Flows
GRCL
Gracell Biotechnologies Inc.
GRCL (NASDAQ)
Period Ending: LTM
(Last Twelve Months)
2022
12-31
2021
12-31
2020
12-31
2019
12-31
2018
12-31
Report Filing: 2023-09-30 2023-04-25 2022-04-22 2021-04-23 2019-12-31 2018-12-31
Net Income/Starting Line -498 -4,163 -451.8 -211.9 -138.7 -60.79
Cash From Operating Activities 0 -3,307 -304.6 -198.1 -135.4 -61.86
Depreciation and Amortization 0 531.1 60.27 21.59 5.12 2.99
Deferred Income Tax 0 0 0 0 0 0
Stock Based Compensation 0 165.1 60.38 0 0 0
Other Non-Cash Items 498 55.97 1.3 2.91 -2.56 0
Changes in Working Capital 0 103.3 25.26 -10.75 0.703 -4.05
Accounts Receivable 0 0 0 0 0 0
Inventory 0 0 0 0 0 0
Accounts Payable 0 0 0 0 0 0
Deferred Revenue 0 0 0 0 0 0
Other Working Capital 0 103.3 25.26 -10.75 0.703 -4.05
Cash From Investing Activities 0 -331.2 -41.62 -93.94 41.37 -113.4
Investments in Property Plant and Equipment 0 -331.6 -56.74 -79.4 -56.43 -11.36
Payments for Acquisitions 0 1,790 10 28.05 -0.098 0
Purchases of Securities 0 -1,790 -10 -28.05 -80.2 -335
Sales and Maturities of Investments 0 1,790 25.13 13.51 178 233
Other Investing Activities 0 -1,790 -10 -28.05 0.098 0
Cash From Financing Activities 0 228.3 1,456 756.5 394.8 138.7
Debt Repayment 0 0 0 0 0 0
Common Stock Issued 0 0 1,449 0 0 0
Common Stock Repurchased 0 0 0 0 -44.7 0
Dividends Paid 0 0 0 0 0 0
Other Financing Activities 0 228.3 1,456 756.5 394.8 138.7
Effect of Forex Changes on Cash 0 844.8 -35.32 -22.13 -0.603 0
Net Change in Cash 243.5 -2,565 1,075 442.2 300.2 -36.52
Cash at Beginning of Period 1,434 12,532 754.3 312.1 11.89 48.41
Cash at End of Period 1,677 9,967 1,829 754.3 312.1 11.89
Free Cash Flow 0 -3,639 -361.3 -277.5 -191.8 -73.21
Operating Cash Flow 0 -3,307 -304.6 -198.1 -135.4 -61.86
Capital Expenditure 0 -331.6 -56.74 -79.4 -56.43 -11.36
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us